Rinsho Shinkeigaku (Clinical Neurology)

Symposium 06

Diagnostic and therapeutic strategy for acyclovir-resistant herpes encephalitis

Masayuki Saijo, M.D., Ph.D.1)

1)Department of Virology 1, National Institute of Infectious Diseases

Acyclovir (ACV), which inhibits the replication of herpes simplex virus, is the standard drug for the treatment of herpes simplex encephalitis. Thanks to the introduction of ACV, the morbidity and mortality of HSE patients have significantly improved. However, the disease is still the severe infection, because it makes some patients with HSE suffer from severe consequences. The sensitivity test of the etiological HSV to ACV is very difficult due to the inability of isolation of the virus from cerebrospinal fluid (CSF). The cases of the ACV treatment-resistant HSE patients have been reported. However, these cases were not virologically confirmed. The first case of encephalitis in newborn baby with HSE caused by an ACV-resistant HSV-1, which was virologically confirmed, was reported by our group. According to the sensitivity profile of the causative viruses to antiviral drugs, the drugs of choice for HSE should be properly considered. Strategy for diagnoses of HSE including antiviral sensitivity assessment and selection of drugs in HSE is reviewed.
Full Text of this Article in Japanese PDF (455K)

(CLINICA NEUROL, 54: 1024|1027, 2014)
key words: herpes simplex encephalitis, acyclovir, sensitivity assay, viral thymidine kinase, cerebrospinal fluid

(Received: 21-May-14)